Hepatic Artery Chemoembolization (TACE) Technique and Dictation

PROCEDURE: 

  1. Superior mesenteric artery angiogram
  2. Celiac axis arteriogram
  3. Hepatic artery angiogram
  4. Chemoembolization of the subselective  ___ hepatic artery
  5. Post-embolization angiogram of the subselective     hepatic artery
  6. Limited right common femoral artery angiogram and deployment of a StarClose closure device

 

DATE OF PROCEDURE:    

INDICATION:    -year-old     with a history of hepatocellular carcinoma who is referred for local regional therapy with drug eluting beads.

MEDICATIONS: Versed and Fentanyl were titrated to effect for moderate sedation.  Premedications given per protocol.

OPERATOR: John Doe, MD (Attending)/Jane Doe, MD (Fellow)    

CONTRAST:    

FLUOROSCOPY TIME:     minutes

ACCESS SITE: Right common femoral artery

 

PROCEDURE:

The risks, benefits, and alternatives to the procedure and sedation were explained to the patient, and written informed consent obtained.

With the patient in the supine position, the right groin was prepped and draped in standard sterile fashion. The skin and subcutaneous tissue overlying the right common femoral artery were infiltrated with 2% lidocaine for local anesthetic. The common femoral artery was accessed with a micropuncture needle. A 0.018″ Nitinol wire was advanced through the needle into the artery. The needle was exchanged for 5 French transitional catheter. The wire and inner dilator were removed and 0.035″ Bentson wire was advanced into the artery. The transitional catheter was exchanged for a 5 French vascular sheath, and the sheath was attached to a heparinized, pressurized bag of saline.  

A 5 French Sim-I Glidecath was advanced over the Bentson wire and used to select the superior mesenteric artery. Digital subtraction angiography was performed.  Next, the Glidecath was used to select the celiac axis. Digital subtraction angiography was performed. A 2.4 French Renegade STC catheter was advanced over a 0.014″ Transend guidewire coaxially through the Glidecath into the right hepatic artery and a corresponding arteriogram was obtained. The catheter was further subselectively advanced into the anterior branches of the right hepatic lobe and a corresponding arteriogram was obtained. Subsequently, this vessel was embolized using 100-300 micron LC Beads coated with Doxorubicin. The catheter was then removed and disposed of appropriately. 

A right common femoral angiogram was obtained through the sheath.  The sheath was removed and the arteriotomy was closed with a StarClose device. A sterile dressing was applied. The patient tolerated the procedure well and left the angiography suite in stable condition without any immediate postprocedural complications. 

 

FINDINGS:

  1. Superior mesenteric arteriogram does not demonstrate an accessory right hepatic artery.
  2. Celiac axis arteriogram demonstrates conventional anatomy.  There is tumor blush arising from    
  3. Post embolization images demonstrate near stasis of flow to the targeted lesions.
  4. Limited right common femoral angiogram demonstrates adequate puncture site above the bifurcation and below the deep internal epigastric artery, adequate for closure device.

 

IMPRESSION: Successful chemoembolization of a ________hepatocellular carcinoma as described.

Frequently Asked Questions

What is hepatic artery chemoembolization (TACE)?

Hepatic artery chemoembolization, or TACE, is a procedure used to treat liver cancer by delivering chemotherapy directly to the liver tumor. This is done by inserting a catheter into the hepatic artery and releasing chemotherapy-coated beads, which cut off the blood supply to the tumor and deliver the drug directly to it, minimizing systemic exposure.

How is the TACE procedure performed?

During TACE, a catheter is inserted through the femoral artery in the groin and guided to the hepatic artery. Using imaging techniques like digital subtraction angiography, the catheter is positioned near the tumor. Drug-eluting beads are then released to block the blood supply to the tumor and deliver chemotherapy directly to it, targeting the cancer cells more effectively.

What are the risks and benefits of hepatic artery chemoembolization?

The benefits of TACE include targeted chemotherapy delivery and reduced side effects compared to systemic chemotherapy. However, risks can include infection, bleeding, liver damage, and post-embolization syndrome, which involves fever and pain. It is crucial to discuss these with your healthcare provider to determine if TACE is suitable for you.

Who is a candidate for TACE?

TACE is typically recommended for patients with intermediate-stage hepatocellular carcinoma (HCC) that is not amenable to surgical removal or radiofrequency ablation. Candidates usually have preserved liver function and no significant portal vein thrombosis. Each patient's suitability is assessed based on their overall health and liver function.

What should I expect after a TACE procedure?

After TACE, patients may experience mild to moderate pain, fever, and nausea, often referred to as post-embolization syndrome. These symptoms usually resolve within a week. Patients are monitored for complications and may require a short hospital stay. Follow-up imaging is necessary to assess the treatment's effectiveness and plan further management.

How does TACE differ from systemic chemotherapy?

Unlike systemic chemotherapy, which circulates throughout the body, TACE delivers chemotherapy directly to the liver tumor. This localized approach increases the concentration of the drug at the tumor site while reducing its systemic exposure, potentially leading to fewer overall side effects and improved targeting of cancer cells.

What imaging techniques are used in TACE?

In TACE, digital subtraction angiography is used to visualize blood vessels and guide the catheter to the liver. This imaging technique provides high-contrast images by subtracting pre-contrast images from post-contrast ones, allowing for precise catheter placement and effective delivery of the treatment.

What is the role of the StarClose closure device in TACE?

The StarClose closure device is used to seal the femoral artery puncture site after the TACE procedure. It aids in achieving hemostasis, which reduces bleeding and allows for faster recovery, enabling patients to mobilize more quickly post-procedure.

Still have questions?

Ask our vascular team — plain answers, no cost, no obligation. If it's about your own care, we'll connect you with a specialist.

Having fever, spreading redness, chest pain, or trouble breathing? Contact your doctor or seek emergency care now — don’t wait on a reply here.

Attorney reviewing a case? Request a board-certified medical expert →

📬 Stay Updated

Get the latest vascular education content delivered to your inbox.